TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: ADP-A2M4CD8 in HLA-A2+ Subjects With MAGE-A4 Positive Esophageal or Esophagogastric Junction Cancers (SURPASS-2)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Key Inclusion Criteria:~* Age ≥18 and \<75 years~* Diagnosis of Esophageal cancer or Esophagogastric junction cancer.~* Previously received treatment for advanced or metastatic disease.~* Measurable disease according to RECIST v1.1.~* HLA-A\*02 positive~* Tumor shows MAGE-A4 expression confirmed by central laboratory.~* ECOG Performance Status of 0 or1.~* Left ventricular ejection fraction (LVEF) ≥50%.~Note: other protocol defined Inclusion criteria may apply~Key exclusion criteria~1. Positive for any HLA-A\*02 allele other than: one of the inclusion alleles~2. History of allergic reactions attributed to compounds of similar chemical or biologic composition to fludarabine, cyclophosphamide or other agents used in the study~3. Active autoimmune or immune mediated disease~4. Leptomeningeal disease, carcinomatous meningitis or symptomatic CNS metastases~5. Other prior malignancy that is not considered by the Investigator to be in complete remission. Clinically significant cardiovascular disease~6. Uncontrolled intercurrent illness~7. Active infection with human immunodeficiency virus, hepatitis B virus, hepatitis C virus, or human T cell leukemia virus~8. Pregnant or breastfeeding~Note: other protocol defined Inclusion/Exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Autologous genetically modified ADP-A2M4CD8 cells (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Treatment of Giardia Lamblia Infections in Children

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* clinical symptoms could be explained by giardiasis AND~* fecal samples will test positive for the presence of G.lamblia in Uusimaa laboratory (HUSLAB)~Exclusion Criteria:~* age \<6 mo or \>10 years~* weight \<9.5 kg~* the absence of symptoms~* co-infection with another pathogen, which may cause giardiasis-like symptoms

- Gender: ALL
- Minimum Age: 6 Months
- Maximum Age: 10 Years
- Healthy Volunteers: f

Study Arms:
- Metronidazole (Type: EXPERIMENTAL): Patients will be given rectal metronidazole (Flagyl) 500 mg/dose for children weighing 10-14,9 kg, 1000 mg/dose for those weighing 15-29,9 kg and 1500 mg/dose for those weighing 30-44,9 kg. Suppositories will not be halved. Patients will be given 1 dose/day for 3 days.
- Tinidazole (Type: ACTIVE_COMPARATOR): Patients will be treated with a standard regimen of oral tinidazole (Fasigyn) at a single dose of 50 mg/kg, maximum 2 g/dose

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Anti-arrhythmic Therapy vs Catheter Ablation as First Line Treatment for AICD Shock Prevention

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* ≥ 18 and ≤ 85 years old~* Able to provide informed consent~* AICD implanted for primary prophylaxis against sudden cardiac death~* AICD implanted for secondary prophylaxis against spontaneous or inducible sustained VT without any reversible causes~* CAD with prior myocardial infarction (\>60 days prior to enrollment)~* AICD or ECG documentation of ventricular arrhythmia responsible for appropriate AICD therapy (\> 3 ATP or ≥ 1 appropriate Shock)~Exclusion Criteria:~* Contraindication or allergy to contrast media, routine procedural medications or catheter materials~* Contraindication to an interventional procedure~* Current or previous (within 3 months) antiarrhythmic therapy~* Absolute contraindication to amiodarone or other AAD~* New York Heart Association (NYHA) functional class IV~* Stroke within the past 90 days~* Unstable angina~* Hypertrophic cardiomyopathy, Non-ischemic dilated cardiomyopathy, Arrhythmogenic Right Ventricular Dysplasia, Brugada Syndrome, Catecholamine sensitive polymorphic VT or long QT syndrome~* Subjects with active ischemia that are eligible for revascularization~* Life expectancy less than 6 months~* Incessant or multiple episodes of VT requiring immediate therapy with medications or ablation~* Untreated hypothyroidism or hyperthyroidism. Subjects who are euthyroid on thyroid hormone replacement therapy are acceptable.~* Current enrollment in another investigational drug or device study.~* Presence of any other condition that the investigator feels would be problematic or would restrict or limit the participation of the Subject for the entire study period.~* Absolute contra-indication to the use of heparin and or warfarin.~* Documented intra-atrial thrombus, ventricular thrombus (\< 6 months after detection of thrombus), tumor, or another abnormality, which precludes catheter introduction.~* Previous VT ablation~* Are pregnant.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Anti-arrhythmic drug therapy (Type: ACTIVE_COMPARATOR): Oral and/or intravenous loading doses of Sotalol, mexiletine, procainamide or amiodarone as first line therapy. Drug chosen is preference of the treating physician. May use single or combination of AAD. Loading doses as per standard dosing guidelines for VT. Subjects on amiodarone should receive oral maintenance dose of at least 200 mg/day.
- Catheter ablation (Type: ACTIVE_COMPARATOR): Ventricular tachycardia (VT) Catheter ablation, using a standardized VT ablation procedure protocol.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Electromyographic Assessment of Onset and Recovery of Neuromuscular Blockade

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_CONTROL
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* American Society of Anesthesiologists Status I to III patients requiring neuromuscular blockade in the operating room will be eligible for enrollment~Exclusion Criteria:~* 1) presence of an underlying neuromuscular disease; 2) use of drugs known to interfere with neuromuscular transmission (antiseizure medications, anticholinesterases, magnesium sulfate); 3) presence of renal or hepatic disease; or 4) procedures preventing access to at least one of the upper extremities.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Acceleromyography group (Type: None): Train-of-four ratio calculation (TOF-Watch-SX-Bluestar enterprise)
- Electromyography group (Type: None): Train-of-four ratio calculation (T4-EMG)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Lidocaine, Esmolol, or Placebo to Relieve IV Propofol Pain

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2/PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* 18-60 years of age~* ASA 1-3~* Elective surgical procedure~Exclusion Criteria:~* BMI ≥ 45~* Pregnancy~* Requirement for RSI or awake intubation~* Suspected or known difficult airway~* Contraindication to IV in either upper extremity~* Chronic pain syndrome including fibromyalgia~* Use of opioids, NSAIDs, or other analgesics within 24 hours (including preoperative PO Celebrex, Lyrica, Tylenol, etc.)~* Any use of opioids in the past three months~* Significant cardiopulmonary or hepatic dysfunction~* Hypersensitivity to study medications

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Lidocaine (Type: ACTIVE_COMPARATOR): 1 mg/kg lidocaine to a max of 100 mg
- Esmolol (Type: ACTIVE_COMPARATOR): 0.5 mg/kg esmolol to a max of 50 mg
- Placebo (Type: PLACEBO_COMPARATOR): Saline water

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: FET-PET/MRI for Surgical Assessment of Pediatric Brain Tumors

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: EARLY_PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Patient must have a known or suspected primary brain tumor with a non-enhancing component with planned standard of care surgical resection. Patients with newly diagnosed or recurrent brain tumors are eligible.~2. Tumors with non-enhancing regions will be defined as T2/FLAIR hyperintensity extending at least 0.5 cm beyond areas of enhancement as assessed by MRI.~3. Patient must be 18 years of age or younger at the time of study enrollment.~4. Patient must have measurable disease defined as tumor measurable in two perpendicular dimensions on MRI greater than 1 cm.~5. Patient must have a life expectancy greater than 8 weeks.~6. Patient must be able to undergo FET-PET/MRI without sedation.~7. Females with childbearing potential must have a negative urine β-hCG test on the day of procedure or a serum hCG test within 48 hours prior to the administration FET. Females who have not reached menarche will not require pregnancy testing.~Exclusion Criteria:~1. Patient must not be receiving an investigational or standard of care anti-cancer drug within 6 months prior to the FET-PET/MRI study.~2. Patient must not have received radiation therapy within the past 6 months.~3. Patient must not have a contraindication to contrast-enhanced MRI (e.g. renal insufficiency, incompatible implant).~4. Patient must not be pregnant or breast feeding.~5. Patient must not have been treated for another cancer within 5 years with the exception of cutaneous basal cell carcinoma or squamous cell carcinoma.~6. Patients must not have a history of brain metastases.

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- FET-PET/MRI (Type: EXPERIMENTAL): O-(2-\[F-18\]FET)-L-tyrosine (FET) for brain PET/MRI

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Kinetics of Microparticles Under Chemotherapy in Patients With Gastric or Pancreatic Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* First-line chemotherapy indicated and accepted by the patient for pancreatic cancer or gastric cancer~* Confirmed diagnosis of pancreatic cancer or gastric cancer~* Free subject, without guardianship or trusteeship or subordination~* Patient benefiting from a social security scheme or benefiting through a third party~* Consent given by the patient after clear and fair information about the study~Exclusion Criteria:~* Age \< 18yo~* Life expectancy ≤10days~* Deep vein thrombosis ou pulmonary embolism ≤3months~* Patient unable to receive chemotherapy (sepsis, acute coronary syndrome, recent stroke, heparin-induced thrombocytopenia, disseminated intravascular coagulation)~* Person enjoying enhanced protection, namely minors, persons deprived of their liberty by a judicial or administrative decision, persons staying in a health or social institution, adults under legal protection, and finally patients in emergency situations~* Pregnant or lactating woman and woman of childbearing age lacking effective contraception

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- kinetics of microparticles under chemotherapy (Type: EXPERIMENTAL): kinetics of microparticles under chemotherapy in patients with pancreatic or gastric cancer by serial measurements of microparticles procoagulant activity.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Treatment of Chronic Antibody-mediated Rejection in Kidney Transplant With Acthar

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Age \>18 years~* Morphologic diagnosis of CAMR, by light \&/or electron microscopy any time after transplantation~* Current or previously documented donor-specific antibody (DSA) and/or focal or diffuse peritubular capillary C4d staining by immunohistochemistry~* eGFR\>25 ml/min~Exclusion Criteria:~* Diagnosis of malignancy within a year prior to enrollment (except cured cutaneous basal cell or squamous cell carcinoma).~* Lack of evidence of antibody involvement~* Pregnancy, lactation, or refusal to use birth control in women of child bearing potential~* Active infection, or history of HIV~* History of liver or thoracic transplant

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Acthar (Type: EXPERIMENTAL): The study cohort. In this cohort Acthar gel will be administered to the enrolled patient with chrnic AMR.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: The Hemophilia Inhibitor Eradication Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Male adults or children \> 4 months of age.~2. Severe hemophilia A (FVIII \< 0.01 U/ml).~3. Current or past high-responding inhibitor, anti-FVIII \>= 5.0 B.U., ITI-refractory or ITI-naive.~Exclusion Criteria:~1. Acquired hemophilia or any bleeding disorder other than hemophilia A.~2. Current use of Emicizumab, or if used, \> 8 weeks since last treatment.~3. Use of an experimental drug(s).~4. Surgery anticipated in the next 48 weeks.~5. Life expectancy less than 5 years.~6. Patient/parent/caretaker unable or unwilling to keep a personal diary of bleeding frequency and study drug treatment, make monthly visits and blood draws at weeks 4, 8, 12, 24, 36, and 48.~7. Other illness, condition, or reason in the opinion of the investigator that would make the patient unsuitable for the trial.

- Gender: MALE
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Eloctate ITI plus Emicizumab (Type: EXPERIMENTAL): Arm A: Eloctate 100 IU/kg every other day by intravenous infusion plus Emicizumab 1.5 mg/kg subcutaneously (following 3 mg/kg/wk x 4 induction) in children and adults with severe hemophilia A and anti-FVIII inhibitor, continued up to 48 weeks.
- Eloctate ITI (Type: ACTIVE_COMPARATOR): Arm B: Eloctate 100 IU/kg every other day by intravenous infusion in children and adults with severe hemophilia A and anti-FVIII inhibitor, continued up to 48 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: regulatory/approval
Please assess the completion status of the following clinical trial:

Trial Title: The Press Fit Condylar (P.F.C.) Sigma Rotating Platform (RP) TC3 Revision Knee in Revision Knee Arthroplasty

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female subjects over the age of 21 years (and skeletally mature).~* Subjects who are able to give voluntary, written informed consent to participate in this investigation and from whom consent has been obtained.~* Subjects who, in the opinion of the Investigator, are able to understand this investigation, co-operate with the investigational procedures and are willing to return to the hospital for all the required post-operative follow-ups.~* Subjects whose primary diagnosis includes non-inflammatory or inflammatory degenerative joint disease.~* Subjects who require revision of any previous knee arthroplasty.~* Subjects who, in the opinion of the Clinical Investigator, are considered to be suitable for treatment with the investigation device, according to the indications specified in the package insert leaflet.~* Subjects who require revision of the femoral and/or tibial components. (Both components must be replaced as part of the study.)~Exclusion Criteria:~* Subjects who, in the opinion of the Investigator, have an existing condition that would compromise their participation and follow-up in this study (including malignancy, severe osteoporosis or disabling musculoskeletal problems).~* Women who are pregnant.~* Subjects who are known drug or alcohol abusers or with psychological disorders that could affect follow-up care or treatment outcomes.~* Subjects who have participated in a clinical study with an investigational product in the last 60 days (excluding any primary knee replacement study).~* Subjects who are currently involved in any injury litigation claims.~* Subjects with global instability, deficient extensor mechanism or severe bone loss (eg. due to fracture or tumour resection).~* Subjects who have had their contralateral knee replaced within the previous 6-month period.

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- PFC Sigma RP TC3 Revision Knee System (Type: EXPERIMENTAL): Revision knee surgery with the PFC Sigma RP TC3 Revision Knee System (mobile bearing).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Effects of Evening Dose of Immediate Release Methylphenidate on Sleep in Children With ADHD

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Ages 6-12 (inclusive), and able to swallow capsule~2. Children who have been treated with a stable morning dose of Extended Release Methylphenidate or twice daily dose of Immediate Release Methylphenidate for an extended period of time (30 days or longer).~3. DSM V diagnosis of Attention Deficit Hyperactivity Disorder (ADHD): Diagnosis will be assessed on the NIMH Computerized Diagnostic Interview Schedule for Children (C-DISC), and parent and teacher rating scales.~4. Children with any ADHD subtype meeting the above criteria will be eligible, although, it is expected that the majority will be of the combined subtype of ADHD given the associate between this subtype and ODD symptoms. A diagnosis of any of the two Behavioral Insomnia of Childhood (BIC) subtypes associated with delayed SOL (limit setting or combined type) will be required.~5. Sex: male or female~6. Fluent in written and spoken English.~Exclusion Criteria:~1. Age \< 6 years of age or \>12 years of age.~2. Children who have not had Methylphenidate (Extended Release) treatment for an extended period of time (30 days or longer).~3. A diagnosis or suspicion of sleep-disordered breathing will be exclusionary as it is not expected to be impacted by Immediate Release Methylphenidate treatment.~4. Current psychotropics other than Methylphenidate (Extended Release or Immediate Release Methylphenidate). Children prescribed alpha agonists for adjunctive control of ADHD in combination with a MPH product will be allowed to enroll as long as they meet all other entry criteria (i.e. sleep must remained impaired with use of alpha agonist).~5. Regular use of other medications that impact sleep within the last 14 days (i.e.: sedating antihistamines, melatonin).~6. Active medical/psychiatric conditions that impact sleep (i.e.: severe asthma, Autism Spectrum Disorder diagnosis, marked developmental delay, or mood/anxiety disorder).

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: 12 Years
- Healthy Volunteers: f

Study Arms:
- Immediate Release Methylphenidate (Type: ACTIVE_COMPARATOR): With-in subjects trial. Subjects will be randomized to 0.3 mg/kg of Immediate Release Methylphenidate versus placebo over 3-weeks duration
- Placebo (Type: PLACEBO_COMPARATOR): inert placebo ingredient

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Non-Polymer-Based, Rapamycin-Eluting Stents to Prevent Restenosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~Age 18-85 years; Symptoms (stable or unstable angina) or signs of myocardial ischemia; Single de novo diagnosed lesion in a native coronary artery (50-99% DS); Lesion length 8 - 25 mm; Vessel diameter 2.25-3.75 mm; Written informed consent~Exclusion Criteria:~Left main target lesion unprotected by a graft; Ostial and bifurcation target lesion; Severely calcified lesions; Thrombus in target lesion; Tortuosity or angulation of target vessel or lesion; Treatment of nontarget lesions in the same or a different coronary vessel during the index procedure; Contraindications to the study medications; Acute myocardial infarction (\< 48 h); Left ventricular ejection fraction \< 25%; Participation in another trial; Pregnancy or lack of protection against pregnancy during the study Coexisting conditions limiting the life expectancy to less 24 months or that could affect the compliance of patients with protocol; Serum creatinin \>2.0mg/dL; Hemorrhagic diathesis; Leukocyte count \<3500/ml\^3 Platelet count \<100.000/ml\^3

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues